Colchicine for at reducere dine symptomer og lavere inflammationsniveauer, nulstillet på effektiv CPPD -sygdomsbehandling (CRYSTALLIZE)
Et randomiseret, dobbeltblindt, placebokontrolleret forsøg på flere steder i calciumpyrophosphataflejringssygdom
The goal of this clinical trial is to learn if colchicine reduces levels of proteins indicating inflammation in the blood in individuals with calcium pyrophosphate deposition (CPPD) disease. The trial will also test the effect of colchicine on joint symptoms in CPPD disease. The main questions it aims to answer are:
- Does colchicine reduce the level of interleukin 18 (IL-18) in the blood of individuals with CPPD disease?
- Does colchicine reduce pain scores in individuals with CPPD disease?
Researchers will compare colchicine once daily to a placebo (a look-alike pill that contains no drug) to see if colchicine works to treat CPPD disease.
Participants will:
- Take colchicine or a placebo every day for 6 months
- Visit the clinic 3 times in 6 months for joint examinations, surveys, and blood tests. Each visit will last 2-3 hours.
- Speak on the telephone with researchers for about 4 times over 6 months. Each phone call will last about 5 minutes.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Sara Tedeschi, MD, MPH
- E-mail: stedeschi1@bwh.harvard.edu
Undersøgelse Kontakt Backup
- Navn: Brenna Sharp de Flores, Senior Research Coordinator
- Telefonnummer: 617-732-6277
- E-mail: bsharp@bwh.harvard.edu
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Rekruttering
- University of Alabama - Birmingham
-
Kontakt:
- Shelby Gontarz, Clinical Research Coordinator
- E-mail: sgontarz@uab.edu
-
Kontakt:
- Clementino Vong Do Rosario, Clinical Research Coordinator
- Telefonnummer: (205) 975-6410
- E-mail: cvongdorosario@uabmc.edu
-
Ledende efterforsker:
- Angelo Gaffo, MD, MsPH
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California - Los Angeles
-
Kontakt:
- Michelle Ramirez, Clinical Research Coordinator
- Telefonnummer: (310) 825-9956
- E-mail: MichelleRa@mednet.ucla.edu
-
Kontakt:
- Aima Ohiwerei, Clinical Research Coordinator
- Telefonnummer: (310) 825-2598
- E-mail: AOhiwerei@mednet.ucla.edu
-
Ledende efterforsker:
- John Fitzgerald, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02118
- Rekruttering
- Boston University Medical Center/Boston Medical Center
-
Kontakt:
- Sayali Dhamne, Clinical Research Coordinator
- Telefonnummer: (617) 358-9655
- E-mail: scdhamne@bu.edu
-
Kontakt:
- Sneha Sinha, Clinical Research Coordinator
- E-mail: sneha@bu.edu
-
Ledende efterforsker:
- Tuhina Neogi, MD
-
Underforsker:
- Maureen Dubreil, MD
-
Boston, Massachusetts, Forenede Stater, 02118
- Rekruttering
- Brigham and Women's Hospital
-
Kontakt:
- Brenna Sharp de Flores, Senior Research Coordinator
- Telefonnummer: 617-732-6277
- E-mail: bsharp@bwh.harvard.edu
-
Ledende efterforsker:
- Sara Tedeschi, MD, MPH
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
Kontakt:
- Kiley Timler, Clinical Research Coordinator
- Telefonnummer: (414) 955-6875
- E-mail: ktimler@mcw.edu
-
Ledende efterforsker:
- Ann Rosenthal, MD, FACP
-
Underforsker:
- Viktoriya Sabchyshyn, DO
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Provide written informed consent
- Fulfill ACR/EULAR 2023 CPPD classification criteria
- Acute or chronic joint inflammation currently or in the past 3 months, not attributable to another condition (Joint Inflammation defined as: At least 1 joint this is swollen, red, or warm to the touch; with or without corresponding tenderness)
- Pain visual analog scale (pain VAS) >=30 at screening
Exclusion Criteria:
-
Age <40 years
-
Chronic diarrhea
-
Gout, rheumatoid arthritis, psoriatic arthritis, or cirrhosis
-
Ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization)
-
Pregnant or breast-feeding
-
Use of methotrexate, hydroxychloroquine, tocilizumab or canakinumab in the past 4 weeks
-
Use of anakinra, oral glucocorticoid, or intra-articular steroid in the past 1 week
-
Ongoing use of strong CYP3A4 inhibitors per FDA package insert for colchicine
-
Ongoing use of P-glycoprotein inhibitors per FDA package insert for colchicine
-
Known allergy to colchicine
-
Planned joint surgery in the next 6 months
-
CPPD clinical presentation isolated to Crowned Dens Syndrome with no additional peripheral joint involvement
-
Screening labs with any of the following:
- Hemoglobin < 9 g/dL
- WBC <3 x 10^9/L
- Platelets <110 x10^9/L
- Creatinine clearance (CrCl) <30 mL/min
- ALT or AST >3x upper limit of normal (ULN)
-
Patient is considered by investigator to be an unsuitable candidate for the study for any reason
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Placebo |
Placebo capsule, taken by mouth once daily |
|
Eksperimentel: Colchicine
Colchicine |
Colchicine 0.6mg tab, overencapsulated to match placebo capsule, taken by mouth once daily |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Interleukin 18 (IL-18)
Tidsramme: Baseline and Week 24
|
Serum IL-18 |
Baseline and Week 24
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum IL-1b
Tidsramme: Baseline and Week 24
|
Serum IL-1b |
Baseline and Week 24
|
|
Serum IL-17A
Tidsramme: Baseline and Week 24
|
Serum IL-17A |
Baseline and Week 24
|
|
High-sensitivity C-reactive protein (hsCRP)
Tidsramme: Baseline and Week 24
|
High-sensitivity C-reactive protein in blood |
Baseline and Week 24
|
|
IL-1b gene signature expression in PBMCs
Tidsramme: Baseline and Week 24
|
Expression of a panel of genes involved in IL-1b production or signaling, as percentage of total gene expression per cell |
Baseline and Week 24
|
|
Immune cell population frequencies
Tidsramme: Baseline and Week 24
|
Immune cell clusters among PBMCs |
Baseline and Week 24
|
|
Pain visual analog scale (pain VAS)
Tidsramme: Baseline, Week 12, Week 24
|
Severity of pain from CPPD disease/pseudogout, both at rest and with activity, in the past 7 days (range 0-100mm, with 0 indicating no pain) |
Baseline, Week 12, Week 24
|
|
Brief Pain Inventory (Short Form)
Tidsramme: Baseline, Week 12, Week 24
|
Brief Pain Inventory includes two sub-scores: Pain Severity Score (range 0-10, with 0 indicating no pain in the past 24 hours) and Pain Interference Score (range 0-10, with 0 indicating no interference in the past 24 hours) |
Baseline, Week 12, Week 24
|
|
Pain in the past week (PEG [pain intensity [P], interference with enjoyment of life [E], and interference with general activity [G])
Tidsramme: Baseline, Week 12, Week 24
|
3 question instrument, range 0-10, with 0 indicating no pain and no interference in the past week |
Baseline, Week 12, Week 24
|
|
Patient Reported Outcome Measurement Information System (PROMIS)-Physical Function
Tidsramme: Baseline, Week 12, Week 24
|
PROMIS-Physical Function Short Form 10a (T-score range 0-100, with higher scores indicating better physical function) |
Baseline, Week 12, Week 24
|
|
Patient Global Assessment of Response to Treatment
Tidsramme: Week 12, Week 24
|
5 point Likert scale |
Week 12, Week 24
|
|
Patient Global Assessment
Tidsramme: Baseline, Week 12, Week 24
|
Patient Global Assessment of CPPD Disease Activity (range: 0-10) |
Baseline, Week 12, Week 24
|
|
Physician Global Assessment
Tidsramme: Baseline, Week 12, Week 24
|
Physician's Global Assessment of CPPD Disease Activity (range: 0-10) |
Baseline, Week 12, Week 24
|
|
Flare count
Tidsramme: Week 12, Week 24
|
Number of acute calcium pyrophosphate crystal arthritis flares |
Week 12, Week 24
|
|
Adverse events
Tidsramme: Week 12, Week 24
|
Number of expected adverse events and unexpected adverse events |
Week 12, Week 24
|
|
Tender Joint Count
Tidsramme: Baseline, Week 12, Week 24
|
Tender Joint Count |
Baseline, Week 12, Week 24
|
|
Swollen Joint Count
Tidsramme: Baseline, Week 12, Week 24
|
Swollen Joint Count |
Baseline, Week 12, Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2024P003512
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .